Chengdu Tianzhiyi Shangpin Pharmaceutical Technology Co., Ltd.

Primary objective: To compare the differences in the degree and rate of absorption of the single-use lipocaine cream (specification: 30g (1g: lidocaine 25mg, prilocaine 25mg)) produced by Zhejiang Jingwei Pharmaceutical Co., Ltd. and licensed by Chengdu Tianzhiyi Shangpin Pharmaceutical Technology Co., Ltd. and the lipocaine cream (trade name: EMLA®, specification: 30g (1g: lidocaine 25mg, prilocaine 25mg)) not imported into the EU market and licensed by Aspen Pharma Trading Limited in healthy Chinese subjects by using a single-center, randomized, open, two-period crossover, fasting trial design, and evaluate the bioequivalence. Secondary objective: To evaluate the safety of the test and reference preparations of lipocaine cream (specification: 30g (1g: lidocaine 25mg, prilocaine 25mg)) in healthy subjects.